# Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

> **NCT05479240** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Immunotherapy

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** oxaliplatin
- **RADIATION:** short-range radiotherapy

## Key facts

- **NCT ID:** NCT05479240
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05479240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05479240, "Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05479240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*